Generic Medicine Info
May be taken with or without food.
History of acute porphyria.
Special Precautions
Patient with chronic lung disease, diabetes, factors predisposing to cardiac rhythm disturbances. Immunocompromised or severely ill patient. Rule out gastric malignancy or possibility of malignancy prior to initiation of therapy. Renal and hepatic impairment. Children. Pregnancy and lactation. Patient Counselling This drug may cause dizziness, drowsiness or blurred vision, if affected, do not drive or operate machinery. Monitoring Parameters Monitor liver and kidney (e.g. serum creatinine) functions, occult blood with gastrointestinal bleeding, and signs of confusion.
Adverse Reactions
Significant: Rarely, mental confusion, depression, hallucinations. Blood and lymphatic system disorders: Rarely, agranulocytosis, aplastic anaemia, granulocytopenia, haemolytic anaemia, leucopenia, pancytopenia (sometimes with marrow hypoplasia or marrow aplasia), thrombocytopenia. Cardiac disorders: Dyspnoea, rarely, asystole, atrioventricular block, bradycardia (rapid IV administration), tachycardia, ventricular premature contractions. Eye disorders: Rarely, reversible blurred vision. Gastrointestinal disorders: Abdominal pain, constipation, nausea, abdominal distress, diarrhoea, vomiting. General disorders and administration site conditions: Rarely, malaise. Hepatobiliary disorders: Rarely, pancreatitis, cholestatic hepatitis, hepatic failure, hepatitis, jaundice. Immune system disorders: Hypersensitivity reactions (e.g. fever, rash, bronchospasm, eosinophilia), anaphylaxis, angioneurotic oedema). Rarely, erythema multiforme. Infections and infestations: Pneumonia. Injury, poisoning and procedural complications: Pain, burning sensation, pruritus at injection site (IV/IM inj). Investigations: Reversible changes in LFTs, elevated plasma creatinine, increased serum prolactin. Metabolism and nutrition disorders: Rarely, acute porphyria. Musculoskeletal and connective tissue disorders: Rarely, arthralgia, myalgia. Nervous system disorders: Headache (sometimes severe), rarely, involuntary motor activity, dizziness, drowsiness, vertigo, agitation. Psychiatric disorders: Rarely, insomnia. Renal and urinary disorders: Rarely, acute interstitial nephritis. Reproductive system and breast disorders: Rarely, reversible impotence. Skin and subcutaneous tissue disorders: Rash, rarely, alopecia. Vascular disorders: Rarely, vasculitis.
Drug Interactions
Altered prothrombin time and increased serum concentration with coumarin anticoagulants (e.g. warfarin). May reduce the excretion and increase plasma concentrations of procainamide and N-acetylprocainamide (high dose ranitidine). May alter the absorption of pH-dependent drugs which may result in either an increase in absorption (e.g. triazolam, glipizide, midazolam) or decrease in absorption (e.g. atazanavir, gefitnib, ketoconazole, delaviridine). Decreased absorption with co-administration of high dose sucralfate.
CIMS Class
Antacids, Antireflux Agents & Antiulcerants
ATC Classification
A02BA02 - ranitidine ; Belongs to the class of H2-receptor antagonists. Used in the treatment of peptic ulcer and gastro-oesophageal reflux disease (GERD).
Disclaimer: This information is independently developed by CIMS based on ranitidine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in